Charting the path from pioneering
biology to impactful therapeutics.

We are a clinical stage drug development company advancing next generation DNA Damage Response (DDR) therapeutics for the treatment of patients with cancer.

Learn More


Beyond PARP – Next Generation DDR Therapeutics

We are focused on developing next generation therapeutics targeting the DNA Damage Response network ‘beyond PARP’, led by SRA737 (targeting Chk1) and SRA141 (targeting Cdc7).

The DNA Damage Response (DDR) Network

DNA Damage Response (DDR) network, a system of cellular pathways that monitor, signal and repair DNA damage. In cancer cells, replication stress induced by oncogenes (e.g., MYC and RAS) combined with loss of function in tumor suppressors (e.g., TP53 and ATM) results in persistent DNA damage and genomic instability. Targeted inhibition of the remaining components of the DDR network, such as by SRA737 or SRA141, may be synthetically lethal to cancer cells and have utility as a monotherapy in a range of tumor indications.